Contents
Key Takeaways
- ARK Invest acquired approximately 281,000 shares of CRSP valued at roughly $14.82M following a 10% price decline
- The selloff occurred after CRISPR Therapeutics disclosed a $350M private placement
- CRSP represents ARK’s second-biggest position across all ETFs, totaling approximately $500M in exposure
- ARK reduced stakes in 10x Genomics (TXG) and Teradyne (TER) during portfolio adjustments
- Both Seeking Alpha Quant and Wall Street analysts assign CRSP a Buy recommendation
Shares of CRISPR Therapeutics (CRSP) tumbled approximately 10% following the biotech company’s announcement of a $350M private placement. Cathie Wood’s ARK Invest responded by purchasing shares during the decline.
According to ARK’s daily transaction disclosure dated March 11, 2026, the investment firm acquired roughly 281,000 shares of CRSP spread across its various ETFs, representing approximately $14.82M in capital deployed.
This purchase represents a continuation of ARK’s bullish stance on the gene-editing company. During the fourth quarter of 2025, Wood expanded ARK’s CRSP holdings by 7.5%, accumulating approximately 735,000 additional shares. The recent acquisition extends that accumulation pattern.
With a 4.49% weighting and approximately $500M in aggregate exposure, CRSP currently ranks as the second-largest position throughout ARK’s combined ETF portfolio. This represents a substantial commitment to a company still operating without revenue generation.
Private Placement Triggers Sharp Decline
The double-digit percentage drop followed CRISPR Therapeutics‘ disclosure of a $350M private stock offering. Such capital raises typically dilute current shareholders, often resulting in near-term price pressure.
The fundraising effort aligns with the company’s operational reality. Operating without revenue and posting negative operating margins, CRISPR Therapeutics requires continued capital infusions to advance its clinical pipeline.
However, the company maintains a robust financial position — boasting a current ratio of 13.32 alongside a minimal debt-to-equity ratio of 0.11, indicating substantial liquidity paired with conservative leverage.
This financial strength likely contributed to ARK’s willingness to increase exposure during the selloff.
CRISPR Therapeutics’ Development Pipeline
The company’s inaugural commercialized therapy, Casgevy, resulted from collaboration with Vertex Pharmaceuticals and received approval for treating sickle-cell disease and transfusion-dependent beta-thalassemia.
The pipeline extends beyond Casgevy, encompassing development programs focused on immuno-oncology applications, cardiovascular treatments, and stem cell-based approaches for Type 1 diabetes management.
Current market capitalization stands at approximately $5.07 billion based on recent valuations.
Recent insider transaction data shows exclusively selling activity — five separate transactions over the previous three months totaling 163,751 shares disposed, with zero recorded insider purchases.
Portfolio Adjustments Across ARK’s Holdings
While accumulating CRSP shares, ARK simultaneously reduced exposure elsewhere. The firm divested 78,412 shares of 10x Genomics (TXG) representing approximately $1.60M, and sold 21,505 shares of Teradyne (TER) valued at $6.47M.
These transactions appear consistent with standard portfolio rebalancing practices across ARK’s actively managed fund family, rather than signaling negative sentiment toward those specific companies.
From an analyst perspective, CRSP maintains Buy ratings from both Seeking Alpha’s Quant rating system and Wall Street research analysts. The Quant methodology awards particularly strong scores for growth characteristics and momentum factors.
A Seeking Alpha analyst highlighted Casgevy’s market introduction and the company’s cash position as notable strengths, while acknowledging the inherent uncertainty associated with pre-revenue biotechnology investments.
GuruFocus’s GF Value metric currently indicates CRSP trades at a significant premium, assigning a fair value estimate of $16.13, contrasting with the prevailing bullish consensus from sell-side analysts.
CRSP finished the trading session down approximately 10.17% on the day the capital raise was disclosed.
